Copertina

First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Paolo Ghia, Carolyn Owen, John N. Allan, Jacqueline C. Barrientos, Paul M. Barr, Chunxue Shi, Anita Szoke, Christopher Abbazio, Gabriel S. Krigsfeld, Jan A. Burger
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	HemaSphere
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Outcomes and prognostic factors in 3306 patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib outside of clinical trials: A nationwide study
di: Gian Matteo Rigolin, et al.
Pubblicazione: (2024)

Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience
di: Paolo Ghia, et al.
Pubblicazione: (2025)

Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
di: Kostas Stamatopoulos, et al.
Pubblicazione: (2024)

Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia
di: Raúl Córdoba, et al.
Pubblicazione: (2026)

CD49d expression is included in a revised 4‐factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real‐world experience
di: Riccardo Bomben, et al.
Pubblicazione: (2024)

Long‐term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab
di: Arnon P. Kater, et al.
Pubblicazione: (2024)

A spheroid model that recapitulates the protective role of the lymph node microenvironment and serves as a platform for drug testing in chronic lymphocytic leukemia
di: Elisa Lenti, et al.
Pubblicazione: (2025)

NK‐type large granular lymphocyte leukemia comes of age
di: Gianpietro Semenzato, et al.
Pubblicazione: (2025)

Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real‐life experience
di: Idanna Innocenti, et al.
Pubblicazione: (2024)

Extracellular vesicles from chronic lymphocytic leukemia cells promote leukemia aggressiveness by inducing the differentiation of monocytes into nurse‐like cells via an RNA‐dependent mechanism
di: Nathan Dubois, et al.
Pubblicazione: (2025)

Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL
di: Thomas Chatzikonstantinou, et al.
Pubblicazione: (2024)

Chronic lymphocytic leukemia with IGH :: BCL3 ‐translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape
di: Cosima Drewes, et al.
Pubblicazione: (2026)

Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
di: Angela Consagra, et al.
Pubblicazione: (2025)

High levels of global hydroxymethylation predict worse overall survival in MDS patients treated with azacitidine
di: Francesca Tiso, et al.
Pubblicazione: (2025)

Causes of death among patients diagnosed with chronic lymphocytic leukemia: A population‐based study in the Netherlands, 1996–2020
di: Lina van der Straten, et al.
Pubblicazione: (2024)

IL21—STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemia
di: Rosita Del Prete, et al.
Pubblicazione: (2026)

Identification of two epitypes of IGHV unmutated chronic lymphocytic leukemia with distinct B‐cell‐related epigenetic imprinting and genetic alterations
di: Stella Charalampopoulou, et al.
Pubblicazione: (2026)

Comparative analysis of macrophage feeder systems reveals distinct behaviors and key transcriptional shifts in chronic lymphocytic leukemia cells via coculture
di: Viktoria Kohlhas, et al.
Pubblicazione: (2025)

Robust and cost‐effective CRISPR/Cas9 gene editing of primary tumor B cells in Eµ‐TCL1 model of chronic lymphocytic leukemia
di: Rosita Del Prete, et al.
Pubblicazione: (2024)

Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM‐prognostic score (FCM‐PS) for overall survival
di: Aida Santaolalla, et al.
Pubblicazione: (2026)

3D Tumor microenvironment interaction reveals AP‐1 complex regulation and contact‐mediated reprogramming of bone marrow stromal cells in chronic lymphocytic leukemia
di: Jana Lindacher, et al.
Pubblicazione: (2025)

Unveiling relative lymphopenia and elevated monocyte‐to‐lymphocyte count as novel independent adverse prognostic factors in chronic myelomonocytic leukemia (CMML)—Proposal of the objective prognostic index for CMML (OPIC)
di: Xavier Calvo, et al.
Pubblicazione: (2026)

A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRD neg remission after intensive induction
di: Konstanze Döhner, et al.
Pubblicazione: (2025)

Transcriptional profiling directs the classification of acute leukemias of ambiguous lineage into AML, B‐ALL, or T‐ALL
di: Roger Mulet‐Lazaro, et al.
Pubblicazione: (2025)

Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study
di: André Baruchel, et al.
Pubblicazione: (2025)

Inflammatory signaling in the pathogenesis of acute myeloid leukemia
di: Artemis Margrith Baumann, et al.
Pubblicazione: (2025)

Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia
di: Bela Patel, et al.
Pubblicazione: (2024)

De‐diagnosing chronic lymphocytic leukaemia: An ethical and scientific case for changing diagnostic criteria
di: Peter Johnstone, et al.
Pubblicazione: (2025)

Impact of the kinetics of circulating anti‐BCMA CAR‐T cells and normal lymphocytes on the outcome of MM patients
di: Sara Gutiérrez‐Herrero, et al.
Pubblicazione: (2025)

Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐up from the phase III HOVON‐65/GMMG‐HD4 trial
di: Elias K. Mai, et al.
Pubblicazione: (2024)

Hyperdiploid acute lymphoblastic leukemia in children with LZTR1 germline variants
di: Lisa Zipper, et al.
Pubblicazione: (2024)

Mutational signatures and kataegis in pediatric B‐cell precursor acute lymphoblastic leukemia
di: Rebeqa Gunnarsson, et al.
Pubblicazione: (2025)

Chronic graft‐versus‐host disease in long‐term survivors of childhood leukemia
di: Paul Saultier, et al.
Pubblicazione: (2026)

Upregulation of ALDH1 as an adaptive epigenetic response to anthracyclines in acute myeloid leukemia
di: Francesco Leonetti, et al.
Pubblicazione: (2025)

HLA evolutionary divergence score after donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
di: Sophie Le Grand, et al.
Pubblicazione: (2025)

Cell surface surprise: NPM1 is an immune therapy target for acute myeloid leukemia
di: Hansen J. Kosasih, et al.
Pubblicazione: (2025)

Correction to “Influence of donor–recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation”
Pubblicazione: (2024)

HLA diversity is associated with TKI response and treatment‐free remission in chronic myeloid leukemia
di: Charles Toulemonde, et al.
Pubblicazione: (2025)

Neuroinflammatory changes in acute myeloid leukemia: Evidence for blood–brain barrier disruption and glial activation
di: Marta Febo, et al.
Pubblicazione: (2026)

Ponalfil trial for adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia: Long‐term results
di: Josep‐Maria Ribera, et al.
Pubblicazione: (2024)